Recombinant expression and EGFR-binding activity assay of single chain nimotuzumab (nimotuzumab scFv) is reported in this study. The scFv was produced in VH-linker-VL format in Origami™ 2(DE3)pLysS bacterial cells and purified using Ni-TNA resin column. 3-D structure prediction using I-TASSER (Iterative Threading Assembly Refinement) server and analyzing the predicted models using YASARA (Yet Another Scientific Artificial Reality Application) viewer revealed that VH and VL domains assemble into a correctly-folded single chain antibody that is able to bind EGFR. The scFv was evaluated in ELISA and western blot tests and proven to be able to bind EGFR-overexpressing cancer cells (A-431 cells in an efficient manner but unable to recognize canc...
Intact monoclonal antibodies with a high molecular weight tend to have a poor pharmacokinetic profil...
Intact monoclonal antibodies with a high molecular weight tend to have a poor pharmacokinetic profil...
Intact monoclonal antibodies with a high molecular weight tend to have a poor pharmacokinetic profil...
The aim of this study was to produce a humanized single chain antibody (scFv) as a potential improve...
Overexpression of the epidermal growth factor (EGF) receptor (EGFR) in cancer cells correlates with ...
Objective: The cytotoxic property of anti-EGFR-1 monoclonal-antibody nimotuzumab modified with nucle...
EGFr (Epidermal growth factor receptor) overexpression has been detected in many tumors of epithelia...
The epidermal growth factor receptor (EGFR) is regarded as an ideal target for cancer therapy and im...
Cetuximab, a chimeric monoclonal antibody developed for targeting the Epidermal Growth Factor Recept...
Introduction: The antibody display technology (ADT) such as phage display (PD) has substantially imp...
BACKGROUND: Nimotuzumab is a humanized IgG1 monoclonal antibody specifically targeting EGFR. In this...
Background: Nimotuzumab is a humanized IgG1 monoclonal antibody specifically targeting EGFR. In this...
Intact monoclonal antibodies with a high molecular weight tend to have a poor pharmacokinetic profil...
. These authors contributed equally to this work. " These authors also contributed equally to t...
Poster presented at Biomedical Technology Showcase 2006, Philadelphia, PA. Retrieved 18 Aug 2006 fro...
Intact monoclonal antibodies with a high molecular weight tend to have a poor pharmacokinetic profil...
Intact monoclonal antibodies with a high molecular weight tend to have a poor pharmacokinetic profil...
Intact monoclonal antibodies with a high molecular weight tend to have a poor pharmacokinetic profil...
The aim of this study was to produce a humanized single chain antibody (scFv) as a potential improve...
Overexpression of the epidermal growth factor (EGF) receptor (EGFR) in cancer cells correlates with ...
Objective: The cytotoxic property of anti-EGFR-1 monoclonal-antibody nimotuzumab modified with nucle...
EGFr (Epidermal growth factor receptor) overexpression has been detected in many tumors of epithelia...
The epidermal growth factor receptor (EGFR) is regarded as an ideal target for cancer therapy and im...
Cetuximab, a chimeric monoclonal antibody developed for targeting the Epidermal Growth Factor Recept...
Introduction: The antibody display technology (ADT) such as phage display (PD) has substantially imp...
BACKGROUND: Nimotuzumab is a humanized IgG1 monoclonal antibody specifically targeting EGFR. In this...
Background: Nimotuzumab is a humanized IgG1 monoclonal antibody specifically targeting EGFR. In this...
Intact monoclonal antibodies with a high molecular weight tend to have a poor pharmacokinetic profil...
. These authors contributed equally to this work. " These authors also contributed equally to t...
Poster presented at Biomedical Technology Showcase 2006, Philadelphia, PA. Retrieved 18 Aug 2006 fro...
Intact monoclonal antibodies with a high molecular weight tend to have a poor pharmacokinetic profil...
Intact monoclonal antibodies with a high molecular weight tend to have a poor pharmacokinetic profil...
Intact monoclonal antibodies with a high molecular weight tend to have a poor pharmacokinetic profil...